A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

Author： Wilcock G.  

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.20, Iss.10, 2003-01, pp. : 777-789

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Galantamine vs Donepezil in the Treatment of Alzheimer's Disease

By Goldlist B.   Gordon M.   Naglie G.  

Drugs & Aging, Vol. 20, Iss. 15, 2003-01 ,pp. : 1139-1140

Adis International

Access to resources Recommend Favorite

Long-Term Cholinesterase Inhibitor Treatment of Alzheimer’s Disease

By Peter Johannsen  

CNS Drugs, Vol. 18, Iss. 12, 2004-01 ,pp. : 757-768

Adis International

Access to resources Recommend Favorite

The pharmacology of donepezil: a new treatment for Alzheimer’s disease

By Wilkinson D.G.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 1, 1999-11 ,pp. : 121-135

Informa Healthcare

Access to resources Recommend Favorite

Current status and new developments with galantamine in the treatment of Alzheimer’s disease

By Tariot Pierre  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 12, 2001-12 ,pp. : 2027-2049

Informa Healthcare

Access to resources Recommend Favorite

Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer’s disease

By Marco-Contelles José   Rodríguez Carolina   García Antonio G  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 5, 2005-05 ,pp. : 575-587

Informa Healthcare

Access to resources Recommend Favorite